From the outset, our overarching objective has been to create a user-friendly test that can be deployed effectively in the field. This choice has raised several critical questions:
The primary end users of our project are epidemiologists and researchers who have actively contributed to its development. Through their collaboration and insights, we have gained a broader perspective on pathogen detection in mosquitoes and the direct transmission of critical information.
We have taken our project a step further by developing a user-friendly paper-based test that can be accessible to the general public. Our ultimate objective is to market the final test to private pharmaceutical companies. The test results can be seamlessly integrated into a dedicated application that we plan to design. This application will enable direct communication with epidemiologists, facilitating a rapid and efficient surveillance system.
To generate widespread awareness about our device, we conducted public surveys and engaged with individuals from various backgrounds. The paper-based test will be accompanied by a user-friendly manual, simplifying the chemical usage process. Users only need to add the specified chemicals, and upon receiving a signal (positive or negative), they can input the data into the application. The application will then automatically alert epidemiologists and researchers. Our goal is to ensure the affordability of these tests for the general public, making them accessible to a broad audience.
The collected data will be stored in a database, serving as the foundation for model development to assess the severity of outbreaks. Subsequently, government entities, public health organizations, and researchers can collaborate to devise effective strategies for controlling the spread of epidemics.
Prior to making the tests available to the public, we have taken meticulous steps to ensure strict adherence to safety regulations. Right from the project's inception, we have been committed to not violating any GMO regulations. During our in-vivo experiments in the laboratory, we employed mosquitoes infected with the virus, but it's crucial to note that the virus used was deactivated. In this regard, we worked closely with virologists, specifically Dr. Christophe Paupy from MIVEGEC in Montpellier, who provided detailed guidance on virus deactivation procedures.
To maintain safety standards, the kits we provide to users will include materials for deactivating the virus. Additionally, we will supply gloves and strongly recommend the use of lab coats as precautionary measures. In our automated device, the chemicals will be automatically mixed, and the reactions performed, with the information transmitted directly to researchers, further ensuring safety and accuracy.
One challenge we must address is the development of an automated machine capable of precisely mixing various chemicals to produce accurate solutions. Achieving the optimal chemical dosage for each reaction is essential to obtain reliable results.
Another challenge involves standardizing the Internet of Things (IoT) infrastructure to enable seamless information transmission to epidemiologists.
We should also consider the patent status of Sherlock, as it may impact our project's intellectual property rights and collaborations.Ensuring effective and systematic communication between different stakeholders, including public health officials, governmental agencies, NGOs, and researchers, is paramount once epidemiologists receive the results.